Get the Stockscreener App
2.42
1.63%
-0.04
Erasca Inc stock is traded at $2.42, with a volume of 1.47M.
It is down -1.63% in the last 24 hours and up +11.01% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
See More
Previous Close:
$2.46
Open:
$2.43
24h Volume:
1.47M
Relative Volume:
1.05
Market Cap:
$686.48M
Revenue:
-
Net Income/Loss:
$-125.04M
P/E Ratio:
-2.9512
EPS:
-0.82
Net Cash Flow:
$-122.99M
1W Performance:
+1.68%
1M Performance:
+11.01%
6M Performance:
+65.75%
1Y Performance:
-6.56%
1-Day Range:
$2.39
$2.505
1-Week Range:
$2.34
$2.54
52-Week Range:
$1.01
$3.305
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
2.42 | 697.83M | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | -52.09M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Initiated | Stifel | Buy |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-26-25 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | Jefferies | Buy |
| Mar-11-24 | Initiated | CapitalOne | Overweight |
| Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-11-23 | Initiated | H.C. Wainwright | Buy |
| Mar-30-23 | Initiated | Mizuho | Buy |
| Feb-24-23 | Initiated | Goldman | Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
Can Erasca Inc. stock deliver sustainable ROEWeekly Stock Recap & Free Expert Verified Stock Movement Alerts - newser.com
Using fundamentals and technicals on Erasca Inc.Quarterly Portfolio Report & Daily Profit Focused Screening - newser.com
Full technical analysis of Erasca Inc. stockEarnings Performance Report & Risk Controlled Swing Alerts - newser.com
Best data tools to analyze Erasca Inc. stockTrade Analysis Report & Expert-Curated Trade Recommendations - newser.com
How to forecast Erasca Inc. trends using time series2025 Trading Recap & Fast Gaining Stock Strategy Reports - newser.com
Why Erasca Inc. stock remains a top recommendationWeekly Investment Recap & Advanced Technical Signal Analysis - newser.com
Analyzing drawdowns of Erasca Inc. with statistical toolsGap Up & Safe Entry Trade Signal Reports - newser.com
Is Erasca Inc. stock oversold or undervaluedAnalyst Upgrade & Momentum Based Trading Signals - newser.com
Analyzing net buyer seller activity in Erasca Inc.July 2025 Fed Impact & Low Drawdown Investment Strategies - newser.com
Heatmap analysis for Erasca Inc. and competitorsWeekly Stock Report & Risk Managed Investment Strategies - newser.com
Risk vs reward if holding onto Erasca Inc.Weekly Trade Review & Verified Chart Pattern Trade Signals - newser.com
Is Erasca Inc. stock affected by interest rate hikesPrice Action & Weekly High Return Forecasts - newser.com
Understanding Erasca Inc.’s price movementWatch List & Stepwise Trade Signal Guides - newser.com
Is Erasca Inc. still worth holding after the dipJuly 2025 Catalysts & Low Risk Growth Stock Ideas - newser.com
Is Erasca Inc. stock poised for growthEarnings Growth Summary & Entry and Exit Point Strategies - newser.com
Erasca, Inc. Advances in Cancer Treatment with ERAS-0015 Study - TipRanks
Will Erasca Inc. stock maintain growth storyGold Moves & Long-Term Growth Portfolio Plans - newser.com
What analysts say about Erasca Inc stockTrade Execution Strategies & Rapid Profit Growth - earlytimes.in
How Erasca Inc. stock performs in weak economyQuarterly Growth Report & Long-Term Capital Growth Ideas - newser.com
Portfolio Update: Will Erasca Inc. stock maintain growth storyJuly 2025 Rallies & Smart Allocation Stock Reports - Fundação Cultural do Pará
Erasca, Inc. Advances with Promising Phase 1 Study on ERAS-4001 - TipRanks
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):